Creative Planning
CNCR

Creative Planning’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Creative Planning’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-689
Closed -$17K – 4642
2017
Q1 		$17K Buy
+689
New +$15.9K ﹤0.01% 3216
2016
Q4 		– Sell
-100
Closed -$3K – 4639
2016
Q3 		$3K Hold
100
– – ﹤0.01% 4072
2016
Q2 		$2K Hold
100
– – ﹤0.01% 3990
2016
Q1 		$2K Hold
100
– – ﹤0.01% 3930
2015
Q4 		$3K Buy
+100
New +$2.88K ﹤0.01% 3891

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RPG
Risk Paradigm Group Austin, Texas $117M AUM
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Creative Planning's CNCR Position: Q2 2017 in Review

Creative Planning sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2017, closing a stake of 689 shares — an estimated $17K sold.

Creative Planning first reported a position in CNCR in Q4 2015 and held it in 5 quarters. The position peaked at $17K in Q1 2017. 11 funds tracked by Wall St. Rank hold CNCR as of Q2 2017.

  • Creative Planning reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2017 after selling out during the quarter.
  • Creative Planning sold 689 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2017, an estimated $17K.
  • Creative Planning first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 5 quarters.
  • Creative Planning's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $17K in Q1 2017.
  • 11 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2017.

Based on Creative Planning's 13F filing for Q2 2017, filed 12 Jul 2017.